As published by BusinessWire, Code Pharma has announced promising eight-week results for its HIV drug, Gammora, hinting at a possible cure at the cellular level. The findings were presented at the HIV Drug Therapy 2024 Conference in Glasgow, Scotland.
The study included 13 participants who had not previously undergone ART treatment. Seven received 20 mg of Gammora SC with Darunavir-based ART, while six were given ART alone. All participants showed a reduction in viral load, with infected cell death noted in the Gammora group. The strong results have led to an early conclusion of the trial, reducing the need for additional recruitment.